Carlyle, PAI Agree to Sell Women's Health Firm Theramex to Cinven
CG sits 16% above its 52-week low of $35.41.
Summary
Carlyle and PAI Partners agreed to sell specialty pharma company Theramex to rival buyout firm Cinven. Terms weren't disclosed, but the Financial Times reported the deal at €2.6 billion ($2.9 billion). Theramex focuses on women's health — menopause, osteoporosis, contraception, uterine health and fertility — and CEO Robert Stewart said Cinven is the right partner to push for global leadership in the category. For Carlyle this is a realized exit from a portfolio holding, and the reported price is a modest slice of its book rather than a thesis-changing sum. It follows a run of Carlyle deal activity this fall, including the BauWatch acquisition with CVC and the Parallax energy buy, while the Lukoil international assets deal expired in October.
At the time of this announcement, CG was trading at $41.06 on NASDAQ in the Finance sector, with a market capitalization of approximately $14.6B. The 52-week trading range was $35.41 to $67.30. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.